In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Storm Clouds Over the Horizon in Orthopedics?

Executive Summary

A decade ago, the threat of price and margin pressure never materialized for orthopedics companies. Instead, the industry entered a prolonged period of strong pricing, aggressive new technology adoption, and widespread investor support. But some industry observers wonder how long the good times, particularly as expressed by strong pricing, can last, as the gulf between orthopedics suppliers' profits and those of their customers widen. Perhaps even more worrisome: Justice Department investigations into off-label use and how suppliers pay surgeons could seriously disrupt the industry by calling into question long-established practices.
Advertisement

Related Content

Orthopedics Through a Keyhole
Reforming Group Purchasing: How Far is Far Enough?
Orthopedics Through a Keyhole
Reforming Group Purchasing: How Far is Far Enough?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002210

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel